NCT00230308 Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer
| NCT ID | NCT00230308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Head and Neck Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2002-04-02 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2002-04-02 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Through this study, we hope to learn more about the mechanisms, which may contribute to development and progression of head and neck cancer. The long-term goal of this study will be to develop new strategies and drugs for the diagnosis and treatment of head and neck cancer.
Eligibility Criteria
Inclusion Criteria: All patients undergoing surgery at Stanford University for head and neck cancer. Exclusion Criteria: Non-Stanford patients.
Frequently Asked Questions
Who can join the NCT00230308 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00230308 currently recruiting?
Yes, NCT00230308 is actively recruiting participants. Visit ClinicalTrials.gov or contact Stanford University to inquire about joining.
Where is the NCT00230308 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT00230308 clinical trial?
NCT00230308 is sponsored by Stanford University. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.